Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized trial of 5-days-on/2-days-off vs 14-days-on/7-days-off capecitabine as adjuvant therapy for stage II/III colorectal cancer
jRCTs051190049Completed
- Start
- Sep 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of capecitabine in colorectal cancer (CRC) (2 arms). Primary endpoints: Treatment completion rate and Feasibility. Started Sep 2019; status: completed.
02
Drugs
capecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs051190049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051190049.